Highlights

  • Monash IVF FY26 Underlying NPAT is now expected to be between AUD 17 million and AUD 18 million.
  • Australian stimulated cycle volumes declined 4.7% to the end of April on a rolling three-month basis.
  • Monash IVF increased national market share by 1.0 percentage point to 20.1%.
  • International operations are expected to deliver materially higher second-half volumes than FY25.

Monash IVF Group Ltd (ASX:MVF) shares rose 1.49% to AUD 0.68 during the morning session on 12 June 2026 coinciding with the release of market and trading update outlining its revised earnings expectations for FY26. The company advised that it now expects FY26 Underlying Net Profit After Tax (NPAT) to be between AUD 17 million and AUD 18 million, reflecting softer-than-anticipated activity levels across the Australian assisted reproductive technology market during the second half of the financial year.

While the update included a lower earnings outlook, investors appeared to focus on several offsetting factors, including market share gains, growth across international operations and initiatives aimed at improving operational efficiency. Monash IVF shares remain up 3.03% over the past year.

Monash IVF Group is one of Australia's providers of assisted reproductive services and women's imaging solutions. The company operates fertility clinics, ultrasound services and reproductive genetic services across Australia while also maintaining an international fertility presence in Southeast Asia. Through brands including Monash IVF, Repromed, KL Fertility and Sydney Ultrasound for Women, the company supports patients seeking fertility treatment and reproductive healthcare services.

FY26 Earnings Outlook Revised

The key announcement from Monash IVF was a revision to its expected FY26 earnings outcome.

The company now expects FY26 Underlying NPAT to be in the range of AUD 17 million to AUD 18 million. According to management, the revised outlook reflects lower-than-expected activity levels across the Australian assisted reproductive technology (ART) market during the second half of FY26.

The fertility sector is influenced by treatment demand trends, patient activity levels and broader market conditions. Monash IVF noted that recent industry-wide data has pointed to a softer operating environment than previously anticipated.

While the revised guidance represents a more cautious earnings outlook, the company also highlighted several areas where operational performance and market positioning continued to improve.

Australian Fertility Market Experiences Softer Conditions

A major factor behind the updated earnings expectations was the decline in Australian ART market activity.

Based on Medicare data referenced by the company, stimulated cycle volumes across the Australian ART market were down 4.7% on a rolling three-month basis to the end of April compared with the prior corresponding period.

Monash IVF indicated that these market conditions have persisted into May and June, creating ongoing pressure on treatment volumes across the industry.

Stimulated cycles represent an important activity measure within fertility services, and fluctuations in these volumes can influence revenue generation across operators in the sector.

The company attributed the revised earnings outlook primarily to this softer market environment rather than company-specific operational issues.

Market Share Gains Provide a Positive Counterbalance

Despite the broader slowdown in fertility treatment activity, Monash IVF reported an increase in its national market share.

The company stated that its share of the Australian stimulated cycle market increased by 1.0 percentage point to 20.1% on a rolling three-month basis compared with the prior corresponding period.

Management also highlighted that several states recorded notable market share improvements during the period.

The market share increase suggests that while overall industry activity has weakened, Monash IVF has continued to attract a larger proportion of patients within the national fertility market.

For investors, this development may indicate that the company has been able to strengthen its competitive position despite the challenging operating backdrop.

A growing market share can become particularly important during periods of weaker industry demand, as it helps offset some of the impact of lower overall market volumes.

International Operations Deliver Growth

Another area highlighted in the update was the performance of Monash IVF's international operations.

The company reported that its overseas fertility businesses continue to deliver growth, with second-half FY26 treatment volumes expected to be materially higher than those recorded during the prior corresponding period.

Although specific volume figures were not disclosed, management's comments indicate that international markets are contributing positively to the broader business during a period when Australian market conditions remain subdued.

Monash IVF's international segment includes fertility operations across Southeast Asia and forms an important component of the group's longer-term growth strategy.

The stronger international performance provides an additional source of diversification beyond the Australian fertility market.

Clinical Network Expansion Continues

Monash IVF also outlined progress in strengthening its clinical network.

The company has continued adding fertility specialists across Victoria and New South Wales, supporting its broader strategy of enhancing clinical capabilities and patient access.

These appointments have occurred following the introduction of the company's inaugural Chief Medical Officer, Fleur Cattrall.

Expanding the clinical network is an important aspect of fertility service delivery, as specialist expertise plays a key role in patient care and treatment capacity.

The continued recruitment of fertility specialists may support future growth opportunities as market conditions evolve.

Operational Efficiency Initiatives Underway

In addition to expanding its clinical capabilities, Monash IVF has been progressing operational and cost efficiency initiatives announced during its half-year results.

According to the company, these programs are currently being implemented across the business.

However, management noted that the timing of implementation means the benefits have only had a limited effect on FY26 earnings.

The company expects a greater contribution from these initiatives during FY27 as implementation progresses and benefits become more fully realised.

Cost efficiency measures often require time before meaningful financial impacts emerge, particularly when changes involve operational processes, systems or organisational structures.

Investors will likely be monitoring future updates to assess how these initiatives translate into financial performance over the coming financial year.

Management Focused on FY27 Benefits

Chief Executive Officer Victoria Atkinson emphasised that Monash IVF has continued to increase its Australian market share while also taking actions to improve operational performance and reduce costs.

Management indicated that these initiatives are expected to contribute more meaningfully during FY27.

The comments suggest that while FY26 has been affected by weaker market conditions, the company remains focused on positioning the business for future operating improvements.

This approach aligns with the broader strategy outlined in the update, which combines market share growth, clinical network expansion, international development and operational efficiency measures.

Industry Conditions Remain an Important Variable

The latest trading update highlights the extent to which broader industry conditions continue to influence financial performance across fertility service providers.

The decline in stimulated cycle volumes across the Australian market demonstrates that demand trends remain an important consideration for operators within the sector.

At the same time, Monash IVF's ability to increase market share and deliver growth through international operations provides evidence that performance can vary significantly within a softer market environment.

As the company approaches the end of FY26, investors are likely to focus on whether market activity stabilises and how operational initiatives contribute to future earnings outcomes.

Monash IVF has indicated that it will provide a further update when it releases its FY26 full-year results on 24 August 2026.

What This Means for Investors?

Monash IVF's latest trading update contained a lower FY26 earnings outlook, with Underlying NPAT now expected to be between AUD 17 million and AUD 18 million due to softer Australian ART market activity.

However, the announcement also highlighted several favourable developments, including a 1.0 percentage point increase in market share to 20.1%, growth across international operations and ongoing operational improvement initiatives expected to contribute more meaningfully in FY27.

The combination of market share gains, international expansion and future efficiency benefits appears to have helped support investor sentiment despite the revised earnings expectations.